Holocene Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Holocene Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-451,300	Closed	-$118M	–	1022
2022 Q1	$118M	Buy	+451,300	New	+$107M	0.61%	51

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Holocene Advisors's VRTX Position: Q2 2026 in Review

Holocene Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 82% in Q2 2026, selling an estimated $24.5M and leaving 12,384 shares worth $6.15M. The position accounts for 0.01% of the portfolio, ranked #378.

Holocene Advisors first reported a position in VRTX in Q1 2018 and has held it in 16 quarters since. The position peaked at $141M in Q2 2022. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Holocene Advisors held 12,384 shares of Vertex Pharmaceuticals worth $6.15M as of Q2 2026.
Holocene Advisors sold 55,234 Vertex Pharmaceuticals shares in Q2 2026, an estimated $24.5M.
Vertex Pharmaceuticals made up 0.01% of Holocene Advisors's portfolio in Q2 2026, its #378 holding.
Holocene Advisors first reported a position in Vertex Pharmaceuticals in Q1 2018 and has held it in 16 quarters since.
Holocene Advisors's Vertex Pharmaceuticals position peaked at $141M in Q2 2022.
1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Holocene Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.